Vigilare Wealth Management purchased a new stake in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 14,994 shares of the company’s stock, valued at approximately $813,000.
Several other institutional investors and hedge funds also recently bought and sold shares of the business. NewEdge Advisors LLC raised its holdings in ARK Genomic Revolution ETF by 102.6% during the 1st quarter. NewEdge Advisors LLC now owns 24,092 shares of the company’s stock valued at $637,000 after acquiring an additional 12,202 shares during the period. Nwam LLC boosted its holdings in shares of ARK Genomic Revolution ETF by 55.3% in the second quarter. Nwam LLC now owns 31,704 shares of the company’s stock worth $1,333,000 after acquiring an additional 11,294 shares during the period. Gimbal Financial bought a new position in shares of ARK Genomic Revolution ETF in the third quarter worth $6,478,000. Group One Trading LLC grew its position in shares of ARK Genomic Revolution ETF by 168.3% in the first quarter. Group One Trading LLC now owns 45,861 shares of the company’s stock valued at $1,212,000 after purchasing an additional 28,765 shares in the last quarter. Finally, Wealth Management Partners LLC grew its position in shares of ARK Genomic Revolution ETF by 78.1% in the third quarter. Wealth Management Partners LLC now owns 27,319 shares of the company’s stock valued at $1,481,000 after purchasing an additional 11,979 shares in the last quarter.
ARK Genomic Revolution ETF Price Performance
Shares of ARKG opened at $51.40 on Monday. The stock’s 50-day simple moving average is $49.92 and its 200 day simple moving average is $37.37. ARK Genomic Revolution ETF has a 52-week low of $24.60 and a 52-week high of $58.83.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Read More
- Five stocks we like better than ARK Genomic Revolution ETF
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
